Arş. Gör. Nail PAKSOY

Yayın Ağı

Makaleler 21

1. Hormon reseptörü pozitif, HER2 negatif metastatik meme kanseri tanısıyla ribosiklib veya palbosiklib ile letrozol kombinasyon tedavisi verilen hastalarda HER2-düşük ekspresyonunun önemi

kahraman s., Hizal M., Gumusay O., Basaran G., Seyyar M., Sahin E., et al.

Turkish Journal of Clinics and Laboratory , cilt.16, sa.2, ss.255-262, 2025 (Hakemli Dergi)

2. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Kahraman S., Karakaya S., Kaplan M. A., SEZGİN GÖKSU S., Ozturk A., Isleyen Z. S., et al.

Scientific Reports , cilt.14, sa.1, 2024 (SCI-Expanded)

3. Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy

Meagher M. F., Minervini A., Mir M. C., Cerrato C., Rebez G., Autorino R., et al.

European Urology Open Science , cilt.63, ss.71-80, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

4. Therapeutic efficacy of high-dose chemotherapy with autologous stem-cell transplantation in 44 relapsed or refractory germ-cell tumor patients: A retrospective cohort study

Ferhatoglu F., Paksoy N., Khanmammadov N., YILDIZ A., AHMED M. A., Gülbas Z., et al.

Medicine , cilt.103, sa.8, 2024 (SCI-Expanded) Sürdürülebilir Kalkınma

5. The effect of parity, breastfeeding history, and duration on clinical and pathological characteristics of breast cancer patients

Ak N., Tuz Z., Aydin E., Ferhatoğlu F., SARI M., Paksoy N., et al.

Turkish Journal of Medical Sciences , cilt.54, sa.1, ss.229-238, 2024 (SCI-Expanded, Scopus, TRDizin)

6. Single-agent temozolomide as salvage therapy in heavily pretreated metastatic sarcoma patients

Dogan I., Paksoy N., BAŞARAN M.

Journal of Cancer Research and Therapeutics , cilt.20, sa.1, ss.93-97, 2024 (SCI-Expanded)

7. Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression

DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Saip P., AYDINER A.

Scientific Reports , cilt.13, sa.1, 2023 (SCI-Expanded) Sürdürülebilir Kalkınma

8. Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients

DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Ferhatoğlu F., AK N., et al.

Journal of Cancer Research and Clinical Oncology , cilt.149, sa.16, ss.14833-14841, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

9. Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience

Pehlivan M., Paksoy N., Aydin E., BAŞARAN M., EKENEL M.

Medicine , cilt.102, sa.41, 2023 (SCI-Expanded) Sürdürülebilir Kalkınma

10. Efficacy and outcomes of systemic chemotherapy in posttransplant and immunosuppression associated Kaposi sarcoma: Twenty years experience of a tertiary cancer center

Khanmammadov N. A., Paksoy N., DOĞAN İ., Ferhatoğlu F., Saip P., Aydiner A.

Medicine , cilt.102, sa.39, 2023 (SCI-Expanded) Sürdürülebilir Kalkınma

11. Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study

FERHATOĞLU F., ÇAĞATAY T., OKUMUŞ G., AYDINER A., PAKSOY N., VATANSEVER S., et al.

Eurasian Journal of Medical Investigation , cilt.7, sa.2, ss.101-106, 2023 (Hakemli Dergi)

12. Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors

DOĞAN İ., KHANMAMMADOV N., PAKSOY N., VATANSEVER S., SAİP P., AYDINER A.

Eurasian Journal of Pulmonology , cilt.25, sa.1, ss.27-32, 2023 (Hakemli Dergi)

13. Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine

DOĞAN İ., Paksoy N., AK N., VATANSEVER S., Saip P., AYDINER A.

European Journal of Breast Health , cilt.19, sa.2, ss.128-133, 2023 (Scopus)

14. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Kahraman S., Erul E., Seyyar M., GÜMÜŞAY Ö., Bayram E., Demirel B. C., et al.

Future oncology (London, England) , cilt.19, sa.10, ss.727-736, 2023 (SCI-Expanded) Sürdürülebilir Kalkınma

15. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Karacin C., Oksuzoglu B., Demirci A., KESKİNKILIÇ M., Baytemür N. K., Yılmaz F., et al.

BMC cancer , cilt.23, sa.1, ss.136, 2023 (SCI-Expanded)

16. Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: A real-life study

Paksoy N., KHANMAMMADOV N., DOĞAN İ., Ferhatoǧlu F., AHMED M. A., Karaman S., et al.

Medicine (Spain) , cilt.102, sa.5, 2023 (Scopus) Sürdürülebilir Kalkınma

17. Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience

TAŞTEKİN D., Paksoy N., DOĞAN İ., Ferhatoglu F., KHANMAMMADOV N., Bozbey H. U., et al.

Journal of cancer research and therapeutics , cilt.19, sa.2, ss.253-258, 2023 (SCI-Expanded) Sürdürülebilir Kalkınma

18. Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group

GÜRBÜZ M., Kilickap S., BİLİCİ A., Karadurmus N., Sezer A., ŞENDUR M. A. N., et al.

MEDICINE , cilt.101, sa.50, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

19. High-dose chemotherapy followed by autologous stem cell transplantation for adult patients with first relapse of Ewing's sarcoma: A single institution experience

PAKSOY N., FERHATOĞLU F., DOĞAN İ., KHANMAMMADOV N., Iribas Celik A., Gulbas Z., et al.

Medicine (United States) , cilt.101, sa.49, 2022 (SCI-Expanded)

20. Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study

PAKSOY N., KHANMAMMADOV N., DOĞAN İ., FERHATOĞLU F., YILDIZ A., AK N., et al.

Medicine (United States) , cilt.101, sa.45, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

21. Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study

Paksoy N., Ferhatoglu F., DOĞAN İ., Khanmammadov N., Bozbey H. U., KARABULUT S., et al.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.37, sa.4, ss.478-483, 2022 (ESCI)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 1

1. Safety and survival in adult women with platinum sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program-LynTurk study

Esin E., Ahmed M. A., Yildirim H. C., Mandel N. M., Erdemoglu E., SARI M., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 2 - 06 Haziran 2023, (Özet Bildiri)

Metrikler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler